Given that Nrf2 can serve different roles dependent on epithelial or mesenchymal carcinoma cell contexts and that Nrf2 can protect from environmental carcinogenic impacts, acute Nrf2 inhibitor treatment strategies need to be considered to avoid promoting EMT in the first instance or increasing risk of tumor initiation in the second. This evidence concerns the gene NFE2L2 and carcinoma.